Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancers|December 5, 2019
The Emerging Role of <i>ESR1</i> Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine TherapyIrene De Santo, Amelia McCartney, Ilenia Migliaccio, et al.
Cancer Treatment Reviews|February 2, 2019
The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise reviewLorenzo Rossi, Amelia McCartney, Irene De Santo, et al.
Clinical Breast Cancer|July 31, 2019
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast CancerLorenzo Rossi, Amelia McCartney, Emanuela Risi, et al.
Clinical Breast Cancer|December 23, 2020
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast CancerGiuseppina Sanna, Marta Pestrin, Erica Moretti, et al.
Cancers|May 14, 2022
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical PracticeFrancesca Carlino, Anna Diana, Antonio Piccolo, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
European Heart Journal. Cardiovascular Imaging|July 22, 2019
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunctionCiro Santoro, Roberta Esposito, Maria Lembo, et al.
Frontiers in Oncology|January 12, 2019
CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Menopause (New York, N.Y.)|December 30, 2017
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective studyTiziana Pagano, Pasquale De Rosa, Roberta Vallone, et al.
Molecular and Clinical Oncology|April 8, 2020
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report seriesFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Pageof 2